Biblio Discovery — Demo Discovery Service

11 hasil untuk "Luca Paruzzo"

Menampilkan 1–11 · 1,79 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Extramedullary Multiple Myeloma: Challenges and Opportunities

    Matthew Ho; Luca Paruzzo; Janna Minehart dkk.

    Current Oncology, Vol. 32 No. 3 · 2025 · Inggris · DOAJ Scopus

    Extramedullary multiple myeloma (EMM), defined in this review as soft tissue plasmacytomas resulting from hematogenous spread, is characterized by the ability of MM cells to proliferate outside of the bone marrow microenvironment. It is aggressive, often associated with high-risk cytogenetics and…

  2. Artikel Jurnal

    Apoptosis: a Janus bifrons in T-cell immunotherapy

    Marco Ruella; Yong Gu Lee; Nicholas Yang dkk.

    Journal for ImmunoTherapy of Cancer, Vol. 11 No. 4 · 2023 · Inggris · DOAJ Scopus

    Immunotherapy has revolutionized the treatment of cancer. In particular, immune checkpoint blockade, bispecific antibodies, and adoptive T-cell transfer have yielded unprecedented clinical results in hematological malignancies and solid cancers. While T cell-based immunotherapies have multiple…

  3. Artikel Jurnal Teks lengkap

    HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis

    Massimo Berger; Marta Barone; Fabrizio Carnevale-Schianca dkk.

    Transplantology, Vol. 3 No. 1 · 2022 · Inggris · DOAJ Scopus

    HSCT from an unrelated HLA-mismatched donor (MMUD) is one of the alternatives where an HLA-matched donor is not found. The aim of this study was to compare GvHD prophylaxis with anti-thymocyte globulin (ATG) vs. post-transplant cyclophosphamide (PT-Cy). Thirty-nine adult patients were uniformly…

  4. Artikel Jurnal

    SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy

    Evan J Lipson; Charlie Garnett-Benson; William L Redmond dkk.

    Journal for ImmunoTherapy of Cancer, Vol. 13 No. 6 · 2025 · Inggris · DOAJ Scopus

    Cancer immunotherapy has radically changed the management of several malignancies, and dozens of agents have been approved in the past 15 years. While these advances have changed the field, many challenges lie ahead and must be addressed if we are to optimize the management of cancer with these…

  5. Artikel Jurnal

    Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel

    Guido Ghilardi; Luca Paruzzo; Vrutti Patel dkk.

    Journal of Hematology & Oncology, Vol. 17 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Bendamustine has been retrospectively shown to be an effective and safe lymphodepletion regimen prior to the anti-CD19 chimeric antigen receptor T cell (CART) products tisagenlecleucel and axicabtagene ciloleucel, as well as the anti-BCMA CART products idecabtagene vicleucel and…

  6. Artikel Jurnal

    CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma

    Lidia Giraudo; Giulia Cattaneo; Loretta Gammaitoni dkk.

    Journal of Experimental & Clinical Cancer Research, Vol. 42 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Background Even acknowledging the game-changing results achieved in the treatment of metastatic melanoma with the use of immune checkpoint inhibitors (ICI), a large proportion of patients (40–60%) still fail to respond or relapse due to the development of resistance. Alterations in the…

  7. Artikel Jurnal

    Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma

    Luca Paruzzo; Khashayar Eshaghi; Guido Ghilardi dkk.

    Blood Immunology & Cellular Therapy, Vol. 1 No. 2 · 2025 · Inggris · DOAJ

    Abstract: Chimeric antigen receptor T-cell (CART) therapy targeting B-cell maturation antigen (CART-BCMA) is a transformative treatment for multiple myeloma (MM). However, its high cost and the need for specialized centers may limit access for racial and ethnic minority populations (REMPs), who are…

  8. Artikel Jurnal

    Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy

    Michael Schneider; Luca Paruzzo; Federico Stella dkk.

    Nature Communications, Vol. 17 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract Axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are standard-of-care second-line therapies for relapsed or refractory large B-cell lymphomas, yet clinical and immunological predictors of durable benefit remain poorly defined. Here, we retrospectively analyze 64…

  9. Artikel Jurnal

    Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study

    Yunlin Zhang; Ruchi P. Patel; Ki Hyun Kim dkk.

    Molecular Cancer, Vol. 22 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Background Commercial anti-CD19 chimeric antigen receptor T-cell therapies (CART19) are efficacious against advanced B-cell non-Hodgkin lymphoma (NHL); however, most patients ultimately relapse. Several mechanisms contribute to this failure, including CD19-negative escape and CAR T…